{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:03:33Z","timestamp":1766023413673,"version":"3.48.0"},"reference-count":58,"publisher":"e-Century Publishing Corporation","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/lkzc2827","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:04:45Z","timestamp":1756451085000},"page":"3603-3616","source":"Crossref","is-referenced-by-count":0,"title":["Surgical outcomes and prognostic factors of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer"],"prefix":"10.62347","volume":"15","author":[{"given":"Lu","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Matulonis UA. Ovarian cancer. Hematol Oncol Clin North Am 2018; 32: xiii-xiv.","DOI":"10.1016\/j.hoc.2018.09.006"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3892\/ol.2024.14574","article-title":"Ovarian cancer: diagnosis and treatment strategies (review)","volume":"28","author":"Li","year":"2024","unstructured":"Li X, Li Z, Ma H, Li X, Zhai H, Li X, Cheng X, Zhao X, Zhao Z and Hao Z. Ovarian cancer: diagnosis and treatment strategies (review). Oncol Lett 2024; 28: 441.","journal-title":"Oncol Lett"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"151679","DOI":"10.1016\/j.soncn.2024.151679","article-title":"Advanced ovarian cancer patients’ experiences of surgical treatment: a qualitative analysis","volume":"40","author":"Harris","year":"2024","unstructured":"Harris E, Yorke J, Law K, Winter-Roach MB and Taylor S. Advanced ovarian cancer patients’ experiences of surgical treatment: a qualitative analysis. Semin Oncol Nurs 2024; 40: 151679.","journal-title":"Semin Oncol Nurs"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ygyno.2018.08.005","article-title":"Surgical prevention strategies in ovarian cancer","volume":"151","author":"Mallen","year":"2018","unstructured":"Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP and Tworoger SS. Surgical prevention strategies in ovarian cancer. Gynecol Oncol 2018; 151: 166-175.","journal-title":"Gynecol Oncol"},{"key":"ref4","unstructured":"National Health Commission of the People’s Republic of China. Clinical practice of ovarian cancer (2018 edition). J Multidiscip Cancer Manag (Electron Version) 2019; 5: 87-96."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","unstructured":"Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124: 1-5.","journal-title":"Int J Gynaecol Obstet"},{"key":"ref6","unstructured":"Zhou Q, Wu X, Liu J, Li L, Zhu X, Bai P and Sheng G. Guidelines for diagnosis and treatment of ovarian malignant tumors (fourth edition). Chin J Pract Gynecol Obstet 2018."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O’Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM and Bookman MA; participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Clinical research in ovarian cancer: consensus recommendations from the gynecologic cancer intergroup. Lancet Oncol 2022; 23: e374-e384.","DOI":"10.1016\/S1470-2045(22)00139-5"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.","journal-title":"Semin Radiat Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.drudis.2020.04.015","article-title":"Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer","volume":"25","author":"Liu","year":"2020","unstructured":"Liu J, Jiao X and Gao Q. Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. Drug Discov Today 2020; 25: 1232-1238.","journal-title":"Drug Discov Today"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bpobgyn.2016.10.007","article-title":"Surgery for advanced epithelial ovarian cancer","volume":"41","author":"Hacker","year":"2017","unstructured":"Hacker NF and Rao A. Surgery for advanced epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2017; 41: 71-87.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2021.04.002","article-title":"Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer","volume":"162","author":"Fleming","year":"2021","unstructured":"Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH and Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol 2021; 162: 65-71.","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ygyno.2024.08.024","article-title":"Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer","volume":"190","author":"Mokshagundam","year":"2024","unstructured":"Mokshagundam S, McGree ME, Tapia AL, Fought AJ, Ishitani KP, Lee MK, Dowdy SC, Yadav S, Pachman DR and Kumar A. Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 2024; 190: 230-235.","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ejso.2019.11.520","article-title":"Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: a systematic review and meta-analysis","volume":"46","author":"Machida","year":"2020","unstructured":"Machida H, Tokunaga H, Matsuo K, Matsumura N, Kobayashi Y, Tabata T, Kaneuchi M, Nagase S and Mikami M. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2020; 46: 868-875.","journal-title":"Eur J Surg Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"820128","DOI":"10.3389\/fonc.2022.820128","article-title":"Neoadjuvant treatment in ovarian cancer: new perspectives, new challenges","volume":"12","author":"Nikolaidi","year":"2022","unstructured":"Nikolaidi A, Fountzilas E, Fostira F, Psyrri A, Gogas H and Papadimitriou C. Neoadjuvant treatment in ovarian cancer: new perspectives, new challenges. Front Oncol 2022; 12: 820128.","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/10837450.2024.2376075","article-title":"Preparation and anti-tumor activity of paclitaxel silk protein nanoparticles encapsulated by biofilm","volume":"29","author":"Ji","year":"2024","unstructured":"Ji Y, Hao J, Tao X, Li Z, Chen L and Qu N. Preparation and anti-tumor activity of paclitaxel silk protein nanoparticles encapsulated by biofilm. Pharm Dev Technol 2024; 29: 627-638.","journal-title":"Pharm Dev Technol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ejmech.2014.08.036","article-title":"Investigation of in vitro anticancer and DNA strap interactions in live cells using carboplatin type Cu(II) and Zn(II) metalloinsertors","volume":"85","author":"Pravin","year":"2014","unstructured":"Pravin N and Raman N. Investigation of in vitro anticancer and DNA strap interactions in live cells using carboplatin type Cu(II) and Zn(II) metalloinsertors. Eur J Med Chem 2014; 85: 675-687.","journal-title":"Eur J Med Chem"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtcvs.2021.11.094","article-title":"Patterns and influence of nodal metastases after neoadjuvant chemoradiation and R0 resection in esophageal adenocarcinoma","volume":"164","author":"Harrington","year":"2022","unstructured":"Harrington CA, Carr RA, Hsu M, Tan KS, Sihag S, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Park BJ, Rocco G, Rusch VW, Jones DR and Molena D. Patterns and influence of nodal metastases after neoadjuvant chemoradiation and R0 resection in esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2022; 164: 411-419.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/bjs\/znad286","article-title":"Neoadjuvant chemoradiation versus perioperative chemotherapy for oeosphageal adenocarcinoma","volume":"110","author":"Reynolds","year":"2023","unstructured":"Reynolds JV. Neoadjuvant chemoradiation versus perioperative chemotherapy for oeosphageal adenocarcinoma. Br J Surg 2023; 110: 1681-1682.","journal-title":"Br J Surg"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2147\/OTT.S148496","article-title":"Peripheral inflammation\/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy","volume":"11","author":"Qian","year":"2018","unstructured":"Qian Y, Tao J, Li X, Chen H, Lu Q, Yang J, Pan H, Wang C, Zhou W and Liu X. Peripheral inflammation\/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. Onco Targets Ther 2018; 11: 1423-1432.","journal-title":"Onco Targets Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"770663","DOI":"10.3389\/fphar.2021.770663","article-title":"Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early triple-negative breast cancer: a narrative review","volume":"12","author":"Tian","year":"2021","unstructured":"Tian H, Ma D, Tan X, Yan W, Wu X, He C, Zhong L, Zhang Y, Yu B, Zhang Y and Qi X. Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early triple-negative breast cancer: a narrative review. Front Pharmacol 2021; 12: 770663.","journal-title":"Front Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","unstructured":"Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S and Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953.","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M and Swart AM. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-257.","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/02841851221087376","article-title":"Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours","volume":"64","author":"Wang","year":"2023","unstructured":"Wang R, Li X, Li S, Fang S, Zhao C, Yang H and Yang Z. Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours. Acta Radiol 2023; 64: 821-828.","journal-title":"Acta Radiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.3390\/ijms241310479","article-title":"Recent insight about HE4 role in ovarian cancer oncogenesis","volume":"24","author":"Anastasi","year":"2023","unstructured":"Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S and Angeloni A. Recent insight about HE4 role in ovarian cancer oncogenesis. Int J Mol Sci 2023; 24: 10479.","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13048-021-00845-6","article-title":"Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"14","author":"Alegr&#xED","year":"2021","unstructured":"Alegría-Baños JA, Jiménez-López JC, Vergara-Castañeda A, de León DFC, Mohar-Betancourt A, Pérez-Montiel D, Sánchez-Domínguez G, García-Villarejo M, Olivares-Pérez C, Hernández-Constantino Á, González-Santiago A, Clara-Altamirano M, Arela-Quispe L and Prada-Ortega D. Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Ovarian Res 2021; 14: 96.","journal-title":"J Ovarian Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"8401202","DOI":"10.1155\/2022\/8401202","article-title":"Clinical efficacy of Yiqi Yangyin decoction combined with docetaxel on advanced ovarian cancer and the effect on the levels of serum markers VEGF, HE4, and CA125","volume":"2022","author":"Wang","year":"2022","unstructured":"Wang N, Xiao F, Shao H, Shi S and Zhou Y. Clinical efficacy of Yiqi Yangyin decoction combined with docetaxel on advanced ovarian cancer and the effect on the levels of serum markers VEGF, HE4, and CA125. J Healthc Eng 2022; 2022: 8401202.","journal-title":"J Healthc Eng"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"10671","DOI":"10.4081\/ejtm.2022.10671","article-title":"Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients","volume":"32","author":"Saffarieh","year":"2022","unstructured":"Saffarieh E, Nassiri S and Mirmohammadkhani M. Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients. Eur J Transl Myol 2022; 32: 10671.","journal-title":"Eur J Transl Myol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1756-8722-5-34","article-title":"Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness","volume":"5","author":"Predina","year":"2012","unstructured":"Predina JD, Kapoor V, Judy BF, Cheng G, Fridlender ZG, Albelda SM and Singhal S. Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J Hematol Oncol 2012; 5: 34.","journal-title":"J Hematol Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ajpath.2017.06.010","article-title":"Early actions of anti-vascular endothelial growth factor\/vascular endothelial growth factor receptor drugs on angiogenic blood vessels","volume":"187","author":"Sitohy","year":"2017","unstructured":"Sitohy B, Chang S, Sciuto TE, Masse E, Shen M, Kang PM, Jaminet SC, Benjamin LE, Bhatt RS, Dvorak AM, Nagy JA and Dvorak HF. Early actions of anti-vascular endothelial growth factor\/vascular endothelial growth factor receptor drugs on angiogenic blood vessels. Am J Pathol 2017; 187: 2337-2347.","journal-title":"Am J Pathol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.3390\/ijms22094871","article-title":"Vascular endothelial growth factor, a key modulator of the anti-tumor immune response","volume":"22","author":"Geindreau","year":"2021","unstructured":"Geindreau M, Ghiringhelli F and Bruchard M. Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci 2021; 22: 4871.","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"811485","DOI":"10.3389\/fimmu.2021.811485","article-title":"Vascular microenvironment, tumor immunity and immunotherapy","volume":"12","author":"Lamplugh","year":"2021","unstructured":"Lamplugh Z and Fan Y. Vascular microenvironment, tumor immunity and immunotherapy. Front Immunol 2021; 12: 811485.","journal-title":"Front Immunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","unstructured":"Zhang Y and Brekken RA. Direct and indirect regulation of the tumor immune microenvironment by VEGF. J Leukoc Biol 2022; 111: 1269-1286.","journal-title":"J Leukoc Biol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11010-017-3244-1","article-title":"Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy","volume":"444","author":"Babyshkina","year":"2018","unstructured":"Babyshkina N, Zavyalova M, Tarabanovskaya N, Dronova T, Krakhmal N, Slonimskaya E, Kzhyshkowska J, Choynzonov E and Cherdyntseva N. Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Mol Cell Biochem 2018; 444: 197-206.","journal-title":"Mol Cell Biochem"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Hathaway ES, Jennings EQ and Rathmell JC. Immunometabolic maladaptations to the tumor microenvironment. Cold Spring Harb Perspect Med 2024; 14: a041547.","DOI":"10.1101\/cshperspect.a041547"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1418527","DOI":"10.3389\/fimmu.2024.1418527","article-title":"Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy","volume":"15","author":"Lopresti","year":"2024","unstructured":"Lopresti L, Tatangelo V, Baldari CT and Patrussi L. Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy. Front Immunol 2024; 15: 1418527.","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1022942","DOI":"10.3389\/fimmu.2023.1022942","article-title":"Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: a pilot study","volume":"14","author":"Cao","year":"2023","unstructured":"Cao G, Hua D, Li J, Zhang X, Zhang Z, Zhang B, Bei T, Cui L, Chen S, Wang S and Zhu L. Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: a pilot study. Front Immunol 2023; 14: 1022942.","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"104238","DOI":"10.1016\/j.critrevonc.2023.104238","article-title":"Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer","volume":"194","author":"Bao","year":"2024","unstructured":"Bao W and Li Z. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer. Crit Rev Oncol Hematol 2024; 194: 104238.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5694\/mja2.52227","article-title":"Screening and prevention of ovarian cancer","volume":"220","author":"Sideris","year":"2024","unstructured":"Sideris M, Menon U and Manchanda R. Screening and prevention of ovarian cancer. Med J Aust 2024; 220: 264-274.","journal-title":"Med J Aust"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/jjco\/hyac065","article-title":"Current trends in chemotherapy for advanced ovarian cancer","volume":"52","author":"Takahashi","year":"2022","unstructured":"Takahashi N and Takekuma M. Current trends in chemotherapy for advanced ovarian cancer. Jpn J Clin Oncol 2022; 52: 806-815.","journal-title":"Jpn J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000539211","article-title":"Nutritional status indicators predict tolerability to adjuvant chemotherapy in patients with stage II\/III rectal cancer undergoing neoadjuvant chemoradiotherapy","volume":"105","author":"Abe","year":"2024","unstructured":"Abe S, Nozawa H, Sasaki K, Murono K, Emoto S, Yokoyama Y, Matsuzaki H, Nagai Y, Shinagawa T, Sonoda H and Ishihara S. Nutritional status indicators predict tolerability to adjuvant chemotherapy in patients with stage II\/III rectal cancer undergoing neoadjuvant chemoradiotherapy. Digestion 2024; 105: 345-358.","journal-title":"Digestion"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1468279","DOI":"10.3389\/fonc.2024.1468279","article-title":"standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer","volume":"14","author":"Foroughi","year":"2024","unstructured":"Foroughi F, Javadinia SA and Salek R. A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer. Front Oncol 2024; 14: 1468279.","journal-title":"Front Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/13548506.2024.2422113","article-title":"Assessment of quality of life, pain, depression, and body-image in breast cancer patients in neoadjuvant therapy","volume":"30","author":"Vieira Carvalho","year":"2025","unstructured":"Vieira Carvalho A, Lima Barroso VF, Lobo Baeta CC, Soares AN and Drummond-Lage AP. Assessment of quality of life, pain, depression, and body-image in breast cancer patients in neoadjuvant therapy. Psychol Health Med 2025; 30: 325-340.","journal-title":"Psychol Health Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1131385","DOI":"10.3389\/fsurg.2023.1131385","article-title":"Influence of adverse effects of neoadjuvant chemoradiotherapy on the prognosis of patients with early-stage esophageal cancer (cT1b-cT2N0M0) based on the SEER database","volume":"10","author":"Cao","year":"2023","unstructured":"Cao X, Wu B, Li H and Xiong J. Influence of adverse effects of neoadjuvant chemoradiotherapy on the prognosis of patients with early-stage esophageal cancer (cT1b-cT2N0M0) based on the SEER database. Front Surg 2023; 10: 1131385.","journal-title":"Front Surg"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"RA","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ and Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/jamaoncol.2016.4411","article-title":"Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the national cancer database","volume":"3","author":"Rauh-Hain","year":"2017","unstructured":"Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG and Keating NL. Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the national cancer database. JAMA Oncol 2017; 3: 76-82.","journal-title":"JAMA Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"2024","volume":"22","author":"Liu","year":"2024","unstructured":"Liu J, Berchuck A, Backes FJ, Cohhen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD and Armstrong DK. NCCN guidelines® insights: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024. J Natl Compr Canc Netw 2024; 22: 512-519.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1016\/j.ejca.2013.06.013","article-title":"Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European organisation for research and treatment of cancer 55971 randomised trial","volume":"49","author":"van Meurs","year":"2013","unstructured":"van Meurs HS, Tajik P, Hof MH, Veen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Crgote I, Kenter GG, Mol BW, Buist MR and Bossuyt PM. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European organisation for research and treatment of cancer 55971 randomised trial. Eur J Cancer 2013; 49: 3191-3201.","journal-title":"Eur J Cancer"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Ben Yaakov T, Wasserman T, Aknin E and Savir Y. Single-cell analysis of the aged ovarian immune system reveals a shift towards adaptive immunity and attenuated cell function. Elife 2023; 12: e74915.","DOI":"10.7554\/eLife.74915"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ygyno.2018.08.041","article-title":"Disparities in treatment and survival among elderly ovarian cancer patients","volume":"151","author":"Taylor","year":"2018","unstructured":"Taylor JS, He W, Harrison R, Zhao H, Sun CC, Lu KH, Giordano SH and Meyer LA. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol 2018; 151: 269-274.","journal-title":"Gynecol Oncol"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Shao Y, Tang M, Fang L, Wei S, Gao X and Liu W. Prognostic value of tumor size in thymic epithelial tumors: a systematic review and meta-analysis. Medicine (Baltimore) 2022; 101: e31741.","DOI":"10.1097\/MD.0000000000031741"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Do MH, Shi W, Ji L, Ladewig E, Zhang X, Srivastava RM, Capistrano KJ, Edwards C, Malik I, Nixon BG, Stamatiades EG, Liu M, Li S, Li P, Chou C, Xu K, Hsu TW, Wang X, Chan TA, Leslie CS and Li MO. Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis. Immunity 2023; 56: 2555-2569, e5.","DOI":"10.1016\/j.immuni.2023.10.010"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.semdp.2021.09.005","article-title":"Undifferentiated and dedifferentiated soft tissue neoplasms: immunohistochemical surrogates for differential diagnosis","volume":"38","author":"Thway","year":"2021","unstructured":"Thway K and Fisher C. Undifferentiated and dedifferentiated soft tissue neoplasms: immunohistochemical surrogates for differential diagnosis. Semin Diagn Pathol 2021; 38: 170-186.","journal-title":"Semin Diagn Pathol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/aogs.14286","article-title":"Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study","volume":"101","author":"Said","year":"2022","unstructured":"Said SA, van der Aa MA, Veldmate G, de Hullu JA and van Altena AM. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study. Acta Obstet Gynecol Scand 2022; 101: 56-67.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"970918","DOI":"10.3389\/fonc.2022.970918","article-title":"Advanced low grade serous ovarian cancer: a retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers","volume":"12","author":"Di Lorenzo","year":"2022","unstructured":"Di Lorenzo P, Conteduca V, Scarpi E, Adorni M, Multinu F, Garbi A, Betella I, Grassi T, Bianchi T, Di Martino G, Amadori A, Maniglio P, Strada I, Carinelli S, Jaconi M, Aletti G, Zanagnolo V, Maggioni A, Savelli L, De Giorgi U, Landoni F, Colombo N and Fruscio R. Advanced low grade serous ovarian cancer: a retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers. Front Oncol 2022; 12: 970918.","journal-title":"Front Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/ijgc-2020-001505","article-title":"Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer","volume":"31","author":"Greer","year":"2021","unstructured":"Greer A, Gockley A, Manning-Geist B, Melamed A, Sisodia RC, Berkowitz R, Horowitz N, Del Carmen M, Growdon WB and Worley M Jr. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. Int J Gynecol Cancer 2021; 31: 1341-1347.","journal-title":"Int J Gynecol Cancer"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00404-024-07775-w","article-title":"Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer","volume":"311","author":"Donato V","year":"2025","unstructured":"Di Donato V, Caruso G, Golia D’Augè T, Perniola G, Palaia I, Tomao F, Muzii L, Pernazza A, Della Rocca C, Bogani G, Benedetti Panici P and Giannini A. Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer. Arch Gynecol Obstet 2025; 311: 429-436.","journal-title":"Arch Gynecol Obstet"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/8\/ajcr0165317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:33Z","timestamp":1766023113000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/8\/ajcr0165317.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/lkzc2827","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2025]]}}}